What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?
ASH 2020: Practice-changing abstracts for MPN
Update on Management of ET/PV with ruxolitinib – MPN-MDSEU-2020.COM
Pr Jean-Jacques Kiladjian : « Améliorer le diagnostic des cancers du sang doit être une priorité nationale. Des initiatives comme Septembre rouge vont nous y aider.» - Opinion Internationale
OncLive - WATCH: Jean-Jacques Kiladjian, MD, PhD, of... | Facebook
Editorial Board - Magdalen Medical Publishing
Jean-Jacques Kiladjian - Vidéo Dailymotion
Dr. Kiladjian on Ruxolitinib Plus Interferon in MPNs
CONTI-PV: a 2-year follow-up of interferon product AOP2014
MPN Asia 2023
Dr. Jean Jacques Kiladjian at ASH 2017 - PV Reporter
Long-term 5-year data continues to show RESPONSE to ruxolitinib in polycythemia vera - YouTube
ASH 2016 Jean-Jacques Kiladjian Interview - YouTube
What is the news about ropeginterferon?
Auteur - Pr Jean-Jacques KILADJIAN
Faculty – 2nd How to Diagnose and Treat CML / MPN
Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis
Équipe Médicale - Centre d'Investigations Cliniques
J.J. Kiladjian (@jjkiladjian) / Twitter
☎️ Contacts du Dr Jean Jacques Kiladjian, Hematologue à Paris 75010
Auteur - Pr Jean-Jacques KILADJIAN
What's new in myeloproliferative neoplasms?
Jean-Jacques Kiladjian | Page 2 of 5 | VJHemOnc
Dr. Jean Jacques Kiladjian ASH 2018 interview with David ...
Dr. J.J. Kiladjian ASH 2018 Headline Research Studies - PV Reporter
Jean-Jacques Kiladjian | VJHemOnc
J.J. Kiladjian (@jjkiladjian) / Twitter
PV Reporter interviews Dr. Jean-Jacques Kiladjian at ASH 2017, video 1 - YouTube
Results for the follow-up of the RESPONSE study - YouTube
